Literature DB >> 19222529

Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification.

J-W Chung1, G H Lee, K-S Choi, D-H Kim, K W Jung, H J Song, K D Choi, H-Y Jung, J-H Kim, J H Yook, B S Kim, S-J Jang.   

Abstract

The incidence of adenocarcinoma of the esophagogastric junction (AEG) has been increasing in Western countries. It is unclear, however, whether similar changes are occurring in Asia. We therefore investigated the incidence of AEG in Korea, and assessed the clinical characteristics of three types of AEG based on Siewert's classification. We retrospectively reviewed the medical records of 16 811 patients diagnosed with esophageal squamous cell carcinoma (ESC, n= 1450) or gastric noncardiac adenocarcinoma (GNCA, n= 14 751) between 1992 and 2006. The patients were divided into three 5-year cohorts (cohort A [1992-1996], n= 2734, cohort B [1997-2001], n= 5727, and cohort C [2002-2006], n= 8350), and the ratios of AEG (n= 610) to non-AEG (ESC and GNCA) in each cohort were compared. Using Siewert's classification, the tumors were categorized into one of three types, and patient demographic features and 5-year survival rates were compared. The ratio of AEG to non-AEG cases did not change over time (0.037, 0.034, and 0.039 for cohorts A, B, and C, respectively; P= 0.40). Of the 610 patients with AEG, 23 (3.7%) had type 1 tumors, 47 (7.7%) had type 2, and 540 (88.5%) had type 3. The 5-year survival rate of patients with type 1 AEG was much lower (4.8 +/- 4.7%) than that of those with type 2 (47.9 +/- 7.8%) and type 3 (47.4 +/- 2.5%) tumors. Unlike in Western countries, the ratio of AEG to non-AEG cases has not increased over time in Korea. Type 1 AEG was rarer and associated with a more unfavorable prognosis in Korea than in Western countries.

Entities:  

Mesh:

Year:  2009        PMID: 19222529     DOI: 10.1111/j.1442-2050.2009.00946.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  24 in total

Review 1.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

2.  Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study.

Authors:  Kazumasa Fujitani; Isao Miyashiro; Shoki Mikata; Shigeyuki Tamura; Hiroshi Imamura; Johji Hara; Yukinori Kurokawa; Jyunya Fujita; Kazuhiro Nishikawa; Yutaka Kimura; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  Gastric Cancer       Date:  2012-08-16       Impact factor: 7.370

3.  Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients.

Authors:  Akiko Kawano; Takako Eguchi Nakajima; Ichiro Oda; Nobukazu Hokamura; Satoru Iwasa; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Hirofumi Fujii; Yasuhiro Shimada
Journal:  Gastric Cancer       Date:  2013-02-24       Impact factor: 7.370

4.  Comparison of long-term clinical outcomes between endoscopic and surgical resection for early-stage adenocarcinoma of the esophagogastric junction.

Authors:  Hyun Ju Kim; Hyunsoo Chung; Sung Kwan Shin; Hyoung-Il Kim; Jun Chul Park; Sang Kil Lee; Woo Jin Hyung; Yong Chan Lee; Sung Hoon Noh
Journal:  Surg Endosc       Date:  2018-02-07       Impact factor: 4.584

5.  Turning left or right? A comparative analysis in adenocarcinomas of the esophagogastric junction according to the seventh AJCC TNM classification for cancers of the esophagus and stomach: experience in a Chinese single institution.

Authors:  Enhao Zhao; Tianlong Ling; Jia Xu; Gang Zhao; Hui Cao; Simone Giacopuzzi; Maria Bencivenga; Giovanni de Manzoni
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction.

Authors:  Jiang-Wei Xiao; Zi-Lin Liu; Peng-Cheng Ye; Ya-Jun Luo; Zhi-Ming Fu; Qin Zou; Shou-Jiang Wei
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

Review 7.  Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review.

Authors:  Rebekka Schirren; Daniel Reim; Alexander R Novotny
Journal:  Ther Adv Med Oncol       Date:  2015-01       Impact factor: 8.168

8.  Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma.

Authors:  Eun Jeong Gong; Do Hoon Kim; Ji Yong Ahn; Kee Wook Jung; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung; Hee Sung Kim; In-Seob Lee; Beom Su Kim; Moon-Won Yoo; Sung Tae Oh; Jeong Hwan Yook; Byung Sik Kim
Journal:  Gastric Cancer       Date:  2016-12-19       Impact factor: 7.370

Review 9.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Authors:  Brian J Reid; Xiaohong Li; Patricia C Galipeau; Thomas L Vaughan
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

10.  Clinical Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma of the Esophagogastric Junction.

Authors:  Eun Jeong Gong; Do Hoon Kim; Hoonsub So; Ji Yong Ahn; Kee Wook Jung; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung; Jin-Ho Kim
Journal:  Dig Dis Sci       Date:  2016-04-25       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.